<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01140568</url>
  </required_header>
  <id_info>
    <org_study_id>091728</org_study_id>
    <nct_id>NCT01140568</nct_id>
  </id_info>
  <brief_title>Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas</brief_title>
  <official_title>A Phase II Study of PDGFR Kinase Inhibitor in Biomarker-Enriched Recurrent Malignant Gliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David Piccioni, M.D., Ph.D</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the survival, disease response, and side effects of&#xD;
      Tasigna® (nilotinib) in patients who have malignant gliomas and are positive for Platelet&#xD;
      Derived Growth Factor Receptor (PDGFR) amplification. This study is designed to test the&#xD;
      hypothesis that patients with malignant gliomas with PDGFR amplification are sensitive to&#xD;
      PDGFR kinase inhibitors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Malignant gliomas (MG), including anaplastic gliomas (AG) and glioblastoma (GBM), are the&#xD;
      most common primary brain tumor. Standard of care (surgery, radiotherapy, and temozolomide at&#xD;
      initial diagnosis) results in a median survival of only 14 months. For patients with&#xD;
      recurrent disease, conventional chemotherapy is generally ineffective with response rates&#xD;
      &lt;20%. Clearly there is need for improved treatments. Recent genome-wide studies have&#xD;
      confirmed that GBM is a heterogeneous group of diseases that can be subclassified by shared&#xD;
      genetic aberrations. The implication is that, in part, the underlying genetics may determine&#xD;
      responsiveness to treatments and thus allow us to personalize therapy.&#xD;
&#xD;
      This is an, open-label, non-randomized, phase II study with oral nilotinib in adult patients&#xD;
      with biomarker-enriched, recurrent malignant gliomas who have developed tumor progression&#xD;
      after standard therapy. Patients will be treated with oral nilotinib (starting with the&#xD;
      labeled dose of 400 mg) daily until disease progression or intolerance. One cycle is defined&#xD;
      as 28 days.&#xD;
&#xD;
      Approximately 50 evaluable patients will be enrolled in this study, with 32 (grade IV) and 18&#xD;
      (grade III) in separate arms.&#xD;
&#xD;
      All patients will undergo clinical evaluation after each 28-day cycle. Neuroimaging studies&#xD;
      (MRI) will be performed at baseline, 4 weeks, 8 weeks and then after every 2 cycles (8&#xD;
      weeks). If a contraindication for MRI's exists, patients will undergo contrast-enhanced CT&#xD;
      scans. Laboratory tests will be obtained weekly during the first 4 weeks, and then on days 1&#xD;
      and 15 of all subsequent cycles. Patients will remain on study medication unless they develop&#xD;
      tumor progression or unacceptable toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 21, 2010</start_date>
  <completion_date type="Actual">January 2019</completion_date>
  <primary_completion_date type="Actual">October 5, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Who Had 6-month Progression-free Survival.</measure>
    <time_frame>6 months</time_frame>
    <description>Progression was defined by McDonald Criteria: A 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR clear clinical worsening OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>5 years</time_frame>
    <description>How many patients who had decrease in tumor size or complete disappearance of tumor.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Glioma</condition>
  <arm_group>
    <arm_group_label>nilotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will take nilotinib twice daily at the standard dose of 400mg taken by mouth twice a day until disease progression or development of unacceptable side effects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nilotinib</intervention_name>
    <description>400mg po (orally) BID (twice daily)</description>
    <arm_group_label>nilotinib</arm_group_label>
    <other_name>Tasigna</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to provide written informed consent prior to participation in the study and&#xD;
             any related procedures being performed.&#xD;
&#xD;
          -  Participants must have agreed to and signed an authorization for the release of their&#xD;
             protected health information.&#xD;
&#xD;
          -  Subjects must be able to adhere to the dosing and visit schedules, and agree to record&#xD;
             medication times accurately and consistently in a daily diary.&#xD;
&#xD;
          -  Participants must have a life expectancy of at least 8 weeks.&#xD;
&#xD;
          -  Patients greater than 18 years of age.&#xD;
&#xD;
          -  Histologically documented diagnosis of proven glioblastoma (GBM), or anaplastic&#xD;
             astrocytoma (AA), anaplastic oligodendroglioma (AO), and anaplastic mixed&#xD;
             oligoastrocytoma (AMO). Patients are eligible if the original local pathology was&#xD;
             lower-grade glioma. Pathology will be read centrally to confirm diagnosis.&#xD;
&#xD;
          -  Documentation of amplified PDGFRA by fluorescent in-situ hybridization (FISH),&#xD;
             colorimetric in-situ hybridization (CISH), or quantitative PCR from tumor tissue (=&gt;3&#xD;
             copy number). Availability of unstained paraffin slides or the paraffin block of&#xD;
             pretreatment baseline tissue is required for eligibility and for molecular analysis&#xD;
             and would help to identify molecular predictors of outcome (all patients).&#xD;
&#xD;
          -  Participants must have a Karnofsky Performance Status (KPS) ≥ 60.&#xD;
&#xD;
          -  Adequate end organ function, defined as the following:&#xD;
&#xD;
               -  Hematology:&#xD;
&#xD;
                    -  Absolute neutrophil count (ANC) ≥ 1.5 x 109/L&#xD;
&#xD;
                    -  Platelet count ≥ 100 x 109/L&#xD;
&#xD;
                    -  Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
                    -  White blood cell (WBC) count ≥ 3.0 x 109/L&#xD;
&#xD;
               -  Biochemistry:&#xD;
&#xD;
                    -  AST/SGOT and ALT/SGPT ≤ 2.5 x institution's ULN&#xD;
&#xD;
                    -  Total bilirubin ≤ 1.5 x institution's ULN&#xD;
&#xD;
                    -  Serum creatinine ≤ 1.5 x institution's ULN or 24-hour creatinine clearance ≥&#xD;
                       50 ml/min&#xD;
&#xD;
                    -  Alkaline phosphatase (ALP) ≤ 2.5 x ULN unless considered tumor related&#xD;
&#xD;
          -  Patients must have the following laboratory values within normal limits (WNL) at the&#xD;
             local institution lab or corrected to WNL with supplements prior to first dose of&#xD;
             study medication.&#xD;
&#xD;
               -  Potassium (WNL)&#xD;
&#xD;
               -  Magnesium (WNL)&#xD;
&#xD;
               -  Phosphorous (WNL)&#xD;
&#xD;
               -  Calcium (WNL)&#xD;
&#xD;
               -  Coagulation studies:&#xD;
&#xD;
                    -  INR &lt; 1.5&#xD;
&#xD;
                    -  PTT within institution's normal range, unless receiving therapeutic low&#xD;
                       molecular weight heparin&#xD;
&#xD;
          -  Female patients of childbearing potential must have negative pregnancy test within 7&#xD;
             days before initiation of study drug dosing. Postmenopausal women must be amenorrheic&#xD;
             for at least 12 months to be considered of non-childbearing potential. Male and female&#xD;
             patients of reproductive potential must agree to employ an effective barrier method of&#xD;
             birth control throughout the study and for up to 3 months following discontinuation of&#xD;
             study drug.&#xD;
&#xD;
          -  Participants must have an unequivocal progression by magnetic resonance imaging (MRI)&#xD;
             or computed tomography (CT) scan. A scan must be performed within 14 days prior to&#xD;
             registration and on a steroid dose that has been stable for at least 5 days. If the&#xD;
             steroid dose is increased between the date of imaging and registration, a new baseline&#xD;
             MRI/CT is required. The same type of scan, i.e., MRI or CT must be used throughout the&#xD;
             period of protocol treatment for tumor measurement. A patient who develops a&#xD;
             contraindication to undergo an MRI scan during study treatment may remain on study and&#xD;
             undergo contrast enhanced CT scans.&#xD;
&#xD;
          -  Patients must have failed prior radiation therapy and must have an interval of greater&#xD;
             than or equal to 60 days from the completion of radiation therapy to study entry.&#xD;
&#xD;
          -  Subjects must have recovered from the toxic effects of prior therapy. Residual&#xD;
             toxicity from any previous treatment must be ≤ Grade 1.&#xD;
&#xD;
          -  Patients must have sufficient time for recovery from prior therapy: 28 days from any&#xD;
             investigational agent, 28 days from prior cytotoxic therapy (except 23 days from prior&#xD;
             temozolomide, 14 days from vincristine, 42 days from nitrosoureas, 21 days from&#xD;
             procarbazine administration), and 7 days for non-cytotoxic agents, e.g., interferon,&#xD;
             tamoxifen, thalidomide, cis-retinoic acid, etc. (radiosensitizer does not count).&#xD;
&#xD;
          -  Patients with prior therapy that included interstitial brachytherapy or stereotactic&#xD;
             radiosurgery must have confirmation of true progressive disease rather than radiation&#xD;
             necrosis based upon positron emission tomography (PET), Thallium scanning, MR&#xD;
             spectroscopy or surgical documentation of disease.&#xD;
&#xD;
          -  Subjects who have undergone recent resection of recurrent or progressive tumor will be&#xD;
             eligible as long as all of the following conditions apply:&#xD;
&#xD;
               -  Prior to initiating therapy, 4 weeks must have elapsed since surgery;&#xD;
&#xD;
               -  Subjects must have recovered from surgical-related trauma;&#xD;
&#xD;
               -  Wound healing needs to have occurred.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who received PDGFR inhibitors (imatinib, sunitinib, nilotinib, etc.)&#xD;
             previously are excluded (patients who received PDGFR antibody based treatment however&#xD;
             are allowed).&#xD;
&#xD;
          -  History of intratumoral or peritumoral hemorrhage if deemed significant by the&#xD;
             treating physician.&#xD;
&#xD;
          -  For patients requiring anticoagulation therapy, only therapeutic low molecular weight&#xD;
             heparin or factor Xa inhibitors are permitted.&#xD;
&#xD;
          -  Due to the potential interaction between nilotinib and enzyme-inducing anti-epileptic&#xD;
             drugs (EIAED), only patients on non-enzyme inducing anti-epileptic drugs (NEIAED) or&#xD;
             on no anti-epileptic drugs are eligible.&#xD;
&#xD;
          -  Patient is &lt; 3 years free of another primary malignancy except: if the other primary&#xD;
             malignancy is not currently clinically neither significant nor requiring active&#xD;
             intervention, or if other primary malignancy is a basal cell skin cancer or a cervical&#xD;
             carcinoma in situ. Existence of any other malignant disease is not allowed.&#xD;
&#xD;
          -  Female patients who are pregnant or breast-feeding, or intends to become pregnant&#xD;
             during the study.&#xD;
&#xD;
          -  Any significant medical illnesses that in the investigator's opinion cannot be&#xD;
             adequately controlled with appropriate therapy or would compromise the patient's&#xD;
             ability to tolerate this therapy.&#xD;
&#xD;
          -  Patient has a rare hereditary problem of galactose intolerance, severe lactase&#xD;
             deficiency or of glucose-galactose malabsorption.&#xD;
&#xD;
          -  Patients with any disease that will obscure toxicity or dangerously alter drug&#xD;
             metabolism.&#xD;
&#xD;
          -  Patient with electrolyte abnormality (e.g., hypokalemia, hypomagnesemia,&#xD;
             hypophosphatemia, hyperkalemia, hypocalcemia, hyponatremia) unless the level can be&#xD;
             corrected to normal levels prior to initiating study drug.&#xD;
&#xD;
          -  Patient has a known diagnosis of human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
          -  Patient received chemotherapy within 4 weeks (6 weeks for nitrosourea) prior to study&#xD;
             entry, unless the disease is rapidly progressing.&#xD;
&#xD;
          -  Concomitant use of any anti-cancer therapy or radiation therapy, or any other&#xD;
             investigational agent.&#xD;
&#xD;
          -  Impaired cardiac function including any of the following:&#xD;
&#xD;
               -  Congenital long QT syndrome or a known family history of long QT syndrome;&#xD;
&#xD;
               -  History or presence of clinically significant ventricular or atrial&#xD;
                  tachyarrhythmias&#xD;
&#xD;
               -  Clinically significant resting bradycardia (&lt; 50 beats per minute)&#xD;
&#xD;
               -  Inability to monitor the QT interval by ECG&#xD;
&#xD;
               -  QTc &gt; 450 msec on baseline ECG. If QTc &gt; 450 and electrolytes are not within&#xD;
                  normal ranges, electrolytes should be corrected and then the patient re-screened&#xD;
                  for QTc&#xD;
&#xD;
               -  Myocardial infarction within 1 year of starting study drug&#xD;
&#xD;
               -  Other clinically significant heart disease (e.g., unstable angina, congestive&#xD;
                  heart failure, or uncontrolled hypertension)&#xD;
&#xD;
          -  Patients currently receiving treatment with strong CYP3A4 inhibitors and treatment&#xD;
             cannot be either discontinued or switched to a different medication prior to starting&#xD;
             study drug. See link for complete list of CYP3A4 inhibitors&#xD;
             (http://medicine.iupui.edu/clinpharm/ddis/table.asp)&#xD;
&#xD;
          -  Patient currently receiving treatment with any medications that have the potential to&#xD;
             prolong the QT interval and cannot be either discontinued or switched to a different&#xD;
             medication prior to starting study drug. See link for a comprehensive list of agents&#xD;
             that prolong the QT interval&#xD;
             (http://www.azcert.org/medical-pros/drug-lists/printable-drug-list.cfm).&#xD;
&#xD;
          -  Impaired gastrointestinal (GI) function or GI disease that may significantly alter the&#xD;
             absorption of study drug (e.g., ulcerative diseases, uncontrolled nausea, vomiting,&#xD;
             diarrhea, malabsorption syndrome, small bowel resection or gastric bypass surgery).&#xD;
&#xD;
          -  Acute or chronic pancreatic disease.&#xD;
&#xD;
          -  Another malignancy that is clinically significant or requires active intervention&#xD;
             (chemotherapy or radiation)&#xD;
&#xD;
          -  Severe or uncontrolled medical conditions (i.e., uncontrolled diabetes, active or&#xD;
             uncontrolled infection).&#xD;
&#xD;
          -  Acute or chronic liver or severe renal disease&#xD;
&#xD;
          -  History of significant congenital or acquired bleeding disorder.&#xD;
&#xD;
          -  Major surgery within 4 weeks prior to Day 1 of study or who have not recovered from&#xD;
             prior surgery.&#xD;
&#xD;
          -  Treatment with other investigational agents within 30 days of Day 1.&#xD;
&#xD;
          -  History of non-compliance to medical regimens or inability to grant consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Piccioni, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Rebecca and John Moores UCSD Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>June 8, 2010</study_first_submitted>
  <study_first_submitted_qc>June 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2010</study_first_posted>
  <results_first_submitted>April 13, 2020</results_first_submitted>
  <results_first_submitted_qc>April 13, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 24, 2020</results_first_posted>
  <last_update_submitted>April 27, 2020</last_update_submitted>
  <last_update_submitted_qc>April 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>David Piccioni, M.D., Ph.D</investigator_full_name>
    <investigator_title>Assistant Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>glioma</keyword>
  <keyword>PDGFR</keyword>
  <keyword>kinase</keyword>
  <keyword>inhibitor</keyword>
  <keyword>malignant</keyword>
  <keyword>nilotinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>38 people were enrolled in the study and 34 were treated with study drug. When patients came off treatment they moved into survival follow up.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Nilotinib</title>
          <description>Patients will take nilotinib twice daily at the standard dose of 400mg taken by mouth twice a day until disease progression or development of unacceptable side effects.&#xD;
nilotinib: 400mg po (orally) BID (twice daily)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Screen Fail</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated With Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>disease progression</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Screen Fail</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nilotinib</title>
          <description>Patients will take nilotinib twice daily at the standard dose of 400mg taken by mouth twice a day until disease progression or development of unacceptable side effects.&#xD;
nilotinib: 400mg po (orally) BID (twice daily)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Who Had 6-month Progression-free Survival.</title>
        <description>Progression was defined by McDonald Criteria: A 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR clear clinical worsening OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).</description>
        <time_frame>6 months</time_frame>
        <population>38 patients were enrolled, but only 34 were treated</population>
        <group_list>
          <group group_id="O1">
            <title>Nilotinib</title>
            <description>Patients will take nilotinib twice daily at the standard dose of 400mg taken by mouth twice a day until disease progression or development of unacceptable side effects.&#xD;
nilotinib: 400mg po (orally) BID (twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Had 6-month Progression-free Survival.</title>
          <description>Progression was defined by McDonald Criteria: A 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR clear clinical worsening OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).</description>
          <population>38 patients were enrolled, but only 34 were treated</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate</title>
        <description>How many patients who had decrease in tumor size or complete disappearance of tumor.</description>
        <time_frame>5 years</time_frame>
        <population>38 patients enrolled, but only 34 received study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Nilotinib</title>
            <description>Patients will take nilotinib twice daily at the standard dose of 400mg taken by mouth twice a day until disease progression or development of unacceptable side effects.&#xD;
nilotinib: 400mg po (orally) BID (twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate</title>
          <description>How many patients who had decrease in tumor size or complete disappearance of tumor.</description>
          <population>38 patients enrolled, but only 34 received study drug</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 years</time_frame>
      <desc>used clinicaltrials.gov definitions</desc>
      <group_list>
        <group group_id="E1">
          <title>Nilotinib</title>
          <description>Patients will take nilotinib twice daily at the standard dose of 400mg taken by mouth twice a day until disease progression or development of unacceptable side effects.&#xD;
nilotinib: 400mg po (orally) BID (twice daily)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal tissue disorder-other: Muscle Spasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Generalized Muscle Weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Localized Edema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alkaline Phosphatase Increased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>ALT Increase</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>AST Increased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash Acneiform</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lara Rose</name_or_title>
      <organization>UCSD - Moores Cancer Center</organization>
      <phone>858-822-6575</phone>
      <email>ljrose@ucsd.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

